DT-EQUIPMENT-EHF
4.9.2020 11:45:04 CEST | Business Wire | Press release
DT Equipment ehf. (DTE) (www.dtequipment.com ), developers of next-generation analytics technology for metals production and processing, announced today the close of a Series A financing with the new participation of Chrysalix Venture Capital and follow-on investment from Brunnur Ventures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200904005232/en/
Sveinn Gudmundsson, CEO of DTE commented, “We are delighted to welcome Chrysalix onboard as industry-focused investors who not only bring a wealth of both technical and early-stage business-building experience to the table, but do so with a highly collaborative and collegiate joint-team approach. We look forward to continuing to working closely together to further advance our world-leading analytics technologies for metal production and processing, and bringing these to market for customers worldwide.”
Chrysalix Venture Capital is a global venture capital fund with a long history of commercializing step-change innovation for resource intensive industries. The Chrysalix RoboValley Fund invests in intelligent systems enabled by AI, IoT and sensor technologies to achieve significant improvements in productivity and critical business processes. Investors in the fund include Fortune 500 companies, leading corporates, financial institutions, family offices and universities, and a notable cluster of metals producers, such as South32, Severstal and Mitsubishi Corporation.
“Chrysalix is making metals and mining innovation, with resource productivity and intelligent systems, a major theme of our new fund. Working with our strategic investors and high potential start-ups, we accelerate new step-change solutions into the mainstream market,” said Richard MacKellar, Managing Partner at Chrysalix Venture Capital. “DTE’s technology enables accurate real-time sampling of liquid metal in primary and secondary aluminum production. Compositional information in real-time results in increased production and quality, reduced costs, and energy savings for aluminum producers. This is in line with our investment thesis of using intelligent systems to improve the economics, efficiency and environmental sustainability of resource intensive industries, while creating significant value for customers.”
DTE was founded in 2013 by highly experienced aluminum industry professionals, with a vision to transform metals production and processing with next-generation sensors and analytics. Based in Iceland, DTE addresses the high unmet need to complement and replace current slow, expensive and manual methods for process and quality control with real-time, in-line analysis of trace materials. DTE’s platform combines first-in-industry fully automated elemental analyzers, generating real-time data, reference quality elemental composition direct from liquid metal with a powerful software analytics platform for pro-active and predictive process control. Watch our technology in action at https://www.dtequipment.com/liquid-metal-analyzer
Aura Capital Partners acted as corporate advisor to the Company.
About DT Equipment
DTE, based in Reykjavik, Iceland is focused on next-generation industrial metal production process control, towards Industry 4.0. The Company’s flagship DTE-EA product range provides first-in-industry direct sampling and compositional analysis of molten metal, addressing the high unmet need to complement and replace current slow, expensive and manual methods for process and quality control with real-time, in-line analysis of trace materials. Real-time process feedback offers substantial opportunities, including improved production efficiency, energy and process cost savings from faster, more frequent measurements and improved operator safety through limiting the need for human intervention. For more information please visit www.dtequipment.com .
About Chrysalix Venture Capital
Chrysalix is a technology focused venture capital firm that builds, mentors and connects high growth companies. Founded in Vancouver, Canada in 2001, and with offices in Delft, Netherlands, Chrysalix has built its reputation on bringing disruptive innovation to the world’s largest industries by focusing on where technology meets physical science. The firm’s investments include breakthrough technologies like smart mining, 3D printing of steel, fast charging electric vehicle infrastructure, emissions-free solar steam, battery intelligence, C02 capture, wastewater management, and fusion energy. Chrysalix has one of the strongest investment teams in the industry with deep energy, technology and entrepreneurial expertise, and is backed by more than 20 international blue chip industrial and financial investors. Chrysalix latest fund, the Chrysalix RoboValley Fund, is the firm’s second fund under management focused on industrial innovation and is expected to grow to over $120M. For more information please visit: www.chrysalix.com or contact Allison Johnson at ajohnson@chrysalix.com .
About Brunnur Ventures
Brunnur Ventures is a $30m venture capital fund focused on Icelandic start-up companies, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent. The Fund is managed by Brunnur Ventures GP. For more information please visit: www.brunnurventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005232/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom